Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 8/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495113 | 0.91 | CES1 (0.36) | NPC1RAB9AKMT2ARXFP1CASP3 | |
| SCHEMBL480642 | 0.89 | KMT2A (0.39) | MEN1NPC1RAB9AKMT2ARXFP1 | |
| SCHEMBL4491671 | 0.88 | CES1 (0.34) | NPC1RAB9AKMT2ARXFP1CASP3 | |
| SCHEMBL4496965 | 0.87 | LRRK2 (0.37) | F11MEN1KMT2ARXFP1CASP3 | |
| SCHEMBL4499903 | 0.86 | CES1 (0.33) | F11RXFP1CASP3CES1 | |
| SCHEMBL4488163 | 0.85 | LRRK2 (0.36) | F11RXFP1 | |
| SCHEMBL480519 | 0.85 | RXFP1 (0.46) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL4480932 | 0.85 | RXFP1 (0.36) | NPC1RAB9AKMT2ARXFP1CASP3 | |
| SCHEMBL4492820 | 0.85 | PSEN1 (0.34) | RXFP1CASP3CES1 | |
| SCHEMBL4491983 | 0.84 | RXFP1 (0.38) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | F11 1885/4885KLKB1 2581/4885MEN1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.